GCP
AIMT

GSA Capital Partners’s Aimmune Therapeutics AIMT Stock Holding History

GSA Capital Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,610
Closed -$221K – 1861
2019
Q2 		$221K Buy
+10,610
New +$218K 0.02% 1188
2019
Q1 		– Sell
-22,137
Closed -$530K – 1812
2018
Q4 		$530K Buy
22,137
+6,537
+42% +$169K 0.06% 529
2018
Q3 		$426K Buy
+15,600
New +$441K 0.02% 1151
2017
Q3 		– Sell
-21,500
Closed -$442K – 1974
2017
Q2 		$442K Buy
+21,500
New +$410K 0.03% 1067

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's AIMT Position: Q3 2019 in Review

GSA Capital Partners sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 10,610 shares — an estimated $221K sold.

GSA Capital Partners first reported a position in AIMT in Q2 2017 and held it in 4 quarters. The position peaked at $530K in Q4 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • GSA Capital Partners reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • GSA Capital Partners sold 10,610 Aimmune Therapeutics shares in Q3 2019, an estimated $221K.
  • GSA Capital Partners first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 4 quarters.
  • GSA Capital Partners's Aimmune Therapeutics position peaked at $530K in Q4 2018.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on GSA Capital Partners's 13F filing for Q3 2019, filed 12 Nov 2019.